Drug Profile
Stavudine/lamivudine/nevirapine - Strides Arcolab
Alternative Names: lamivudine/nevirapine/stavudine; Lamivudine/stavudine + nevirapine; nevirapine/stavudine/lamivudine; Stavudine/lamivudine + nevirapine; Stavudine/nevirapine/lamivudineLatest Information Update: 23 Nov 2018
Price :
$50
*
At a glance
- Originator Strides Arcolab
- Developer Strides Pharma Science
- Class 3-ring heterocyclic compounds; Antiretrovirals; Azepines; Cyclopropanes; Deoxyribonucleosides; Dideoxynucleosides; Nucleosides; Pyridines; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered HIV-1 infections
Most Recent Events
- 23 Nov 2018 Drug lamivudine/stavudine co-packaged with nevirapine (40mg/150mg+200mg) is not yet available in USA for HIV-1 infections (Strides website, November 2018)
- 23 Nov 2018 Drug lamivudine/stavudine/nevirapine (40mg/150mg/200mg) and (30mg/150mg/200mg) is not yet available in USA for HIV-1 infections (Strides website, November 2018)